Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future

American Journal of Rhinology and Allergy

Volumn 30, Issue 6, 2016, Pages 407-413

  Kennedy, Joshua L ^a,b   Stoner, Ashley N ^a   Borish, Larry ^c,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; ANTIALLERGIC AGENT; KETOROLAC; LEUKOTRIENE;

ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CHRONIC SINUSITIS; DESENSITIZATION; DISEASE COURSE; GASTROINTESTINAL DISEASE; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; SKIN DISEASE; SYMPTOMATOLOGY; ANIMAL; DIFFERENTIAL DIAGNOSIS; DRUG HYPERSENSITIVITY; METABOLISM; PROCEDURES; UNITED STATES;

ANIMALS; ANTI-ALLERGIC AGENTS; ASPIRIN; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; HUMANS; KETOROLAC; LEUKOTRIENES; PREVALENCE; UNITED STATES;

EID: 84995920296     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2016.30.4370     Document Type: Article

References (88)

1. Stevenson DD, and Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118:773-786; quiz 787-788, 2006.
2. Widal F, Abrami P, and Lermoyez J. First complete description of the aspirin idiosyncrasy-Asthma-nasal polyposis syndrome (plus urticaria)-1922 (with a note on aspirin desensitization). By F. Widal, P. Abrami, J. Lermoyez. J Asthma 24:297-300, 1987.
3. Gilbert GB. Unusual idiosyncrasy to aspirin. JAMA 56:1262-1263, 1911.
4. Hirschberg. Anaphylactoid reaction to aspirin (1902). Allergy Proc 11:249-250; discussion 251-252, 1990.
5. Samter M, and Beers RF Jr. Concerning the nature of intolerance to aspirin. J Allergy 40:281-293, 1967.
6. Samter M, and Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68:975-983, 1968.
7. Rajan JP, Wineinger NE, Stevenson DD, and White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-Analysis of the literature. J Allergy Clin Immunol 135:676-681.e1, 2015.
8. Szczeklik A, and Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 55(suppl. 2):S42-S44, 2000.
9. Szczeklik A, Nizankowska E, and Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 16:432-436, 2000.
10. Berges-Gimeno MP, Simon RA, and Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89:474-478, 2002.
11. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 146:76-81, 1992.
12. Perez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 115:1189-1196, 2005.
13. Steinke JW, Bradley D, Arango P, et al. Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: Importance to eosinophilia and asthma. J Allergy Clin Immunol 111:342-349, 2003.
14. Adamjee J, Suh YJ, Park HS, et al. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. J Pathol 209:392-399, 2006.
15. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 101:834-846, 1998.
16. Aksu K, Kurt E, Alatas O, and Gulbas Z. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 35:148-155, 2014.
17. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirinsensitive asthmatic subjects. Am Rev Respir Dis 143:1025-1029, 1991.
18. Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 115: 316-322, 2005.
19. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347:1493-1499, 2002.
20. Maekawa A, Kanaoka Y, Xing W, and Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105:16695-16700, 2008.
21. Nonaka Y, Hiramoto T, and Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337:281-288, 2005.
22. Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206:2543-2555, 2009.
23. Laidlaw TM, and Boyce JA. Aspirin-exacerbated respiratory disease-New prime suspects. N Engl J Med 374:484-488, 2016.
24. Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-Adherent leukocytes. Blood 119:3790-3798, 2012.
25. Stevenson DD, Simon RR, and Zuraw BL. Sensitivity to Aspirin and NSAIDs. Philadelphia: Mosby, 2003.
26. Mascia K, Borish L, Patrie J, et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 94:652-657, 2005.
27. Vanselow NA, and Smith JR. Bronchial asthma induced by indomethacin. Ann Intern Med 66:568-572, 1967.
28. Knowles SR, Drucker AM, Weber EA, and Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. Ann Pharmacother 41:1191-1200, 2007.
29. Kowalski ML, and Makowska J. Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity: Safety of cyclooxygenase-2 inhibitors. Treat Respir Med 5:399-406, 2006.
30. Settipane RA, and Stevenson DD. Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol 84:26-33, 1989.
31. Woessner KM, Simon RA, and Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 46:2201-2206, 2002.
32. Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Immunol Res 6:156-162, 2014.
33. Sommer DD, Rotenberg BW, Sowerby LJ, et al. A novel treatment adjunct for aspirin exacerbated respiratory disease: The low-salicylate diet: A multicenter randomized control crossover trial. Int Forum Allergy Rhinol 6:385-391, 2016.
34. ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 109:621-626, 2002.
35. Cahill KN, Bensko JC, Boyce JA, and Laidlaw TM. Prostaglandin D(2): A dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 135:245-252, 2015.
36. Song WL, Stubbe J, Ricciotti E, et al. Niacin and biosynthesis of PGD(2) by platelet COX-1 in mice and humans. J Clin Invest 122: 1459-1468, 2012.
37. Cardet JC, White AA, Barrett NA, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract 2:208-213, 2014.
38. Brune K, and Hinz B. The discovery and development of antiinflammatory drugs. Arthritis Rheum 50:2391-2399, 2004.
39. Gamboa P, Sanz ML, Caballero MR, et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 34:1448-1457, 2004.
40. Berges-Gimeno MP, Simon RA, and Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 32:1491-1496, 2002.
41. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-Aspirin in aspirin-sensitive asthmatics. Eur Respir J 6:1018-1026, 1993.
42. Pauls JD, Simon RA, Daffern PJ, and Stevenson DD. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 85:40-45, 2000.
43. Lee RU, and Stevenson DD. Aspirin-exacerbated respiratory disease: Evaluation and management. Allergy Asthma Immunol Res 3:3-10, 2011.
44. Jerschow E, Ren Z, Hudes G, et al. Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 116:321-328.e1, 2016.
45. Juergens UR, Christiansen SC, Stevenson DD, and Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 96:148-156, 1995.
46. Divekar R, Hagan J, Rank M, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract 4:665-670, 2016.
47. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184:602-615, 2011.
48. Haccuria A, Michils A, Michiels S, and Van Muylem A. Exhaled nitric oxide: A biomarker integrating both lung function and airway inflammation changes. J Allergy Clin Immunol 134:554-559, 2014.
49. Mastalerz L, Milewski M, Duplaga M, et al. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirininduced asthma. Allergy 52:895-900, 1997.
50. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 157:1187-1194, 1998.
51. Liu T, Garofalo D, Feng C, et al. Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors. J Immunol 194:5061-5068, 2015.
52. Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol 195:3537-3545, 2015.
53. Stevenson DD, and Zuraw BL. Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 24:169-188, 2003.
54. Steinke JW, and Kennedy JL. Leukotriene inhibitors in sinusitis. Curr Infect Dis Rep 14:147-154, 2012.
55. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165:9-14, 2002.
56. Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg 151:575-581, 2014.
57. Esmaeilzadeh H, Nabavi M, Aryan Z, et al. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial. Clin Immunol 160:349-357, 2015.
58. Swierczynska-Krepa M, Sanak M, Bochenek G, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: A double-blind study. J Allergy Clin Immunol 134:883-890, 2014.
59. Xu JJ, Sowerby L, and Rotenberg BW. Aspirin desensitization for aspirin-exacerbated respiratory disease (Samter's Triad): A systematic review of the literature. Int Forum Allergy Rhinol 3:915-920, 2013.
60. Berges-Gimeno MP, Simon RA, and Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111:180-186, 2003.
61. White AA, Stevenson DD, and Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 95:330-335, 2005.
62. Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: A double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 73:500-507, 1984.
63. Forer B, Kivity S, Sade J, and Landsberg R. Aspirin desensitization for ASA triad patients: Prospective study of the rhinologist's perspective. Rhinology 49:95-99, 2011.
64. Sweet JM, Stevenson DD, Simon RA, and Mathison DA. Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis-Asthma. J Allergy Clin Immunol 85(pt. 1):59-65, 1990.
65. Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-Asthma: Long-term outcomes. J Allergy Clin Immunol 98:751-758, 1996.
66. Mendelsohn D, Jeremic G, Wright ED, and Rotenberg BW. Revision rates after endoscopic sinus surgery: A recurrence analysis. Ann Otol Rhinol Laryngol 120:162-166, 2011.
67. Yip J, Yao CM, and Lee JM. State of the art: A systematic review of the surgical management of aspirin exacerbated respiratory disease. Am J Rhinol Allergy 28:493-501, 2014.
68. Gosepath J, Schaefer D, Amedee RG, and Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg 127:316-321, 2001.
69. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: A prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 63:1228-1234, 2008.
70. Menzella F, Piro R, Facciolongo N, et al. Long-term benefits of omalizumab in a patient with severe non-Allergic asthma. Allergy Asthma Clin Immunol 7:9, 2011.
71. de Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-Atopic asthma: Results from a Spanish multicenter registry. J Asthma 50:296-301, 2013.
72. Hayashi H, Mitsui C, Nakatani E, et al. Omalizumab reduces cysteinyl leukotriene and 9alpha,11beta-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 137:1585-1587.e4, 2016.
73. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131:110-116.e1, 2013.
74. Johns CB, and Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 28:287-289, 2014.
75. Clutterbuck EJ, Hirst EM, and Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73:1504-1512, 1989.
76. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128:989-995.e1-8, 2011.
77. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 184:1125-1132, 2011.
78. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118:1133-1141, 2006.
79. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125: 1344-1353.e2, 2010.
80. Varricchi G, Bagnasco D, Borriello F, et al. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: Evidence and unmet needs. Curr Opin Allergy Clin Immunol 16:186-200, 2016.
81. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132:1086-1096.e5, 2013.
82. Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 370:2102-2110, 2014.
83. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial. JAMA 315:469-479, 2016.
84. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of mediumto-high-dose inhaled corticosteroids plus a long-Acting beta agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388:31-44, 2016.
85. Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirinexacerbated respiratory disease. J Allergy Clin Immunol 137:1566-1576.e5, 2016.
86. Ho J, Bailey M, Zaunders J, et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy 45:394-403, 2015.
87. Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25-And IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 12:1055-1062, 2011.
88. Takeshita K, Yamasaki T, Nagao K, et al. CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int Immunol 16:947-959, 2004.